Compare SMID & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | ENLV |
|---|---|---|
| Founded | 1960 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.6M | 149.0M |
| IPO Year | 1996 | 2014 |
| Metric | SMID | ENLV |
|---|---|---|
| Price | $29.40 | $0.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 13.3K | ★ 344.8K |
| Earning Date | 04-14-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $93,446,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $118.16 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $25.60 | $0.51 |
| 52 Week High | $43.62 | $2.10 |
| Indicator | SMID | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 23.78 |
| Support Level | $26.74 | N/A |
| Resistance Level | $36.74 | $1.25 |
| Average True Range (ATR) | 1.49 | 0.05 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 44.35 | 18.34 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.